new glp-1 drugs in development Novo cuts prices 70%, but semaglutide revenue could grow 2026 It Is a Huge Market.

Take depemokimab (brand name Exdensur), a recently approved IL-5 inhibitor for severe asthma: patients need only two doses a year, a dramatic departure from the fortnightly or monthly routines of standard biologics

The body uses L-Carnitine readily for a plethora of cellular functions

Robust, biomarker-integrated trials using standardised, bioavailable formulations and stratifying participants by microbiome and metabolomic profiles are required to identify responders and establish clinical efficacy

Research shows subjects reporting "sleep pressure" within about 2 hours of administration, with sleep time increasing significantly that same night